155 related articles for article (PubMed ID: 35218397)
21. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
22. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
23. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L; Criscuolo M; Broccoli A; Piciocchi A; Varettoni M; Galli E; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Frustaci A; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Offidani M; Casadei B; Nizzoli ME; De Luca ML; Fianchi L; Motta M; Guarnera L; Simonetti E; Visentin A; Vassallo F; Deodato M; Sarlo C; Olivieri A; Falini B; Pulsoni A; Tiacci E; Zinzani PL
Blood Cancer J; 2022 Jul; 12(7):109. PubMed ID: 35853850
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
Nieva J; Bethel K; Saven A
Blood; 2003 Aug; 102(3):810-3. PubMed ID: 12663446
[TBL] [Abstract][Full Text] [Related]
25. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
Yousaf M; Khan MA; Iftikhar R; Chaudary QU; Shahbaz N; Ahmad U; Javed H
J Ayub Med Coll Abbottabad; 2022; 34(4):797-801. PubMed ID: 36566402
[TBL] [Abstract][Full Text] [Related]
26. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
[TBL] [Abstract][Full Text] [Related]
28. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
Broccoli A; Argnani L; Nanni L; Terragna C; Sabattini E; Gabrielli G; Stefoni V; Pellegrini C; Casadei B; Morigi A; Lolli G; Carella M; Coppola PE; Zinzani PL
Am J Hematol; 2021 Oct; 96(10):1204-1210. PubMed ID: 34245477
[TBL] [Abstract][Full Text] [Related]
29. Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian-Indians.
Chatterjee T; Panigrahi I; Mahapatra M; Pati HP; Kumar R; Naithani R; Wadhwa S; Choudhry VP; Saxena R
Indian J Cancer; 2008; 45(2):41-4. PubMed ID: 18626146
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
31. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
Dearden CE; Else M; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():21-4. PubMed ID: 21599603
[TBL] [Abstract][Full Text] [Related]
32. Development of cladribine at Scripps for hairy cell leukemia and current results.
Torrey ML; Sigal DS; Saven A
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():29-33. PubMed ID: 21504293
[TBL] [Abstract][Full Text] [Related]
33. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia.
Yang MH; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):54-8. PubMed ID: 11310372
[TBL] [Abstract][Full Text] [Related]
34. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
35. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
36. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
[TBL] [Abstract][Full Text] [Related]
37. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
38. Treatment of hairy cell leukemia: long-term results in a developing country.
Ruiz-Delgado GJ; Tarín-Arzaga LC; Alarcón-Urdaneta C; Calderón-García J; Gómez-Almaguer D; Ruiz-Argüelles GJ
Hematology; 2012 May; 17(3):140-3. PubMed ID: 22664112
[TBL] [Abstract][Full Text] [Related]
39. Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
Machii T; Chou T; Suzuki M; Ohe Y; Katagiri S; Kitano EK; Kitano K; Fujiyama Y; Izumi T; Shimazaki C; Nanba K; Ohashi Y; Kitani T;
Int J Hematol; 2005 Oct; 82(3):230-5. PubMed ID: 16207596
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
Guest JF; Smith H; Sladkevicius E; Jackson G
Clin Ther; 2009; 31 Pt 2():2398-415. PubMed ID: 20110049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
